Stay updated with breaking news from Lawrencef Eichenfield. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Long-term intermittent use of ruxolitinib cream is well tolerated and provides disease control in adolescent patients with atopic dermatitis (AD), according to a study published online May 2 in the American Journal of Clinical Dermatology.
Experts at the American Academy of Dermatology Annual Meeting shared results of research into various topical and systemic therapies for atopic dermatitis (AD) and hidradenitis suppurativa during a late-breaking abstract session.
Researchers integrated data from two pivotal trials and a long-term extension study.
In the phase 2 study, researchers at 34 sites in four countries randomized 104 patients with mild to moderate AD or psoriasis to receive the topical PDE4 inhibitor or a vehicle once daily for 6 weeks.
These new data highlight the importance of larger trials to evaluate the persistence of this treatment’s efficacy and safety seen here.